Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Boehringer Ingelheim, Rosetta Genomics, Asuragen

Premium

Galapagos Affirms Q4 Guidance, Lowers Full-Year Cash Burn Projections ...

Galapagos said this week that it expects its fourth-quarter 2005 revenues to meet previous guidance of €7.7 million ($9.3 million), and that it expects its full-year cash burn to be lower than its guidance of €7 million.

The Belgian drug discovery company said that the successful integration of product lines from BioFocus, which it acquired in October, plus "financial control measures" enabled it to keep cash burn lower than it had anticipated.

Galapagos, which trades on the Euronext exchange in Brussels and Amsterdam and the London AiM, said it expects revenues for the full year to increase to €11 million, from €7.8 million in 2004.

The company said it plans to publish its full year 2005 results on March 3.


… and Inks Target-Discovery Deal with Boehringer Ingelheim

Also this week, Galapagos said that its BioFocus service division will use its siRNA-based gene collection to provide Boehringer Ingelheim with novel drug targets.

The three-year deal could be worth more than €2 million ($2.4 million), Galapagos said.

Terms of the collaboration call for BioFocus to expand its SilenceSelect siRNA-based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease, and use this assay to run a target-discovery screen, the company said.

Galapagos will receive upfront fees, as well as research and development funding, and stands to receive milestone fees when certain drug-discovery criteria are met.

Additional terms were not provided.


Report: Rosetta Genomics, Asuragen Ink Deal for Prostate Cancer Dx

Rosetta Genomics and Asuragen have signed a deal to develop three new diagnostic products for prostate cancer, Israel's Globes Online reported today.

The products are expected to be available in 2008, according to the article. A Rosetta Genomics spokeswoman declined to confirm the Globes Online article.

As reported by RNAi News last week, Asuragen founder Matt Winkler said that the companies had formed a collaboration (see RNAi News, 1/12/2006). He declined to specify the nature of the deal at that time, and did not provide additional detail in an e-mail to RNAi News this week.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.